LOGIN
ID
PW
MemberShip
2025-09-09 23:11
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
Expanded competitiveness of K-Bio immunotherapies
by
Son, Hyung Min
Aug 26, 2025 06:05am
Korean pharmaceutical and biotech companies are entering the development of immunotherapies, increasing the possibility of 'big deals' with global pharmaceutical companies. As competition for new drugs targeting next-generation immune checkpoint proteins intensifies, Aprogen has begun developing VISTA targets by securing an antibody candidate fr
Company
Jaypirca may be prescribed at general hospitals in Korea
by
Eo, Yun-Ho
Aug 26, 2025 06:04am
The BTK inhibitor Jaypirca may now be prescribed in general hospitals in Korea. According to industry sources on the 22nd, Lilly Korea¡¯s relapsed and refractory mantle cell lymphoma treatment Jaypirca (pirtobrutinib) has passed review of Drug Committees (DCs) at medical institutions in Korea, including Samsung Medical Center, Pusan Unive
Company
'New treatment opportunities rise for acquired hemophilia A'
by
Whang, byung-woo
Aug 25, 2025 06:06am
There is an extremely rare bleeding disorder that affects one in every 100,000 people. It is acquired hemophilia A, a condition in which healthy individuals experience unexplained bruising and severe bleeding throughout the body. Until recently, there were limited treatment options available for emergencies, causing significant challenges for
Company
Lilly seeks Mounjaro¡¯s reimbursement for diabetes in Korea
by
Eo, Yun-Ho
Aug 22, 2025 06:08am
¡®Mounjaro,¡¯ which is causing a roar in the field of obesity treatment, is seeking inclusion in insurance reimbursement for its diabetes indication. According to Dailpharm coverage, Eli Lilly Korea has submitted a reimbursement application for its Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist, and is proceeding with the neces
Company
Leclaza at global crossroads 1 year into FDA approval
by
Moon, sung-ho
Aug 22, 2025 06:06am
One year has passed since Leclaza (lazertinib) received FDA approval in combination with Johnson & Johnson¡¯s Rybrevant (amivantamab). Expanding its influence beyond the United States to Europe and Asia, it has emerged as a global treatment option both in Korea and abroad. In the first half of this year, it recorded an overall survival rate (
Company
Nubeqa gains flexibility with indication expansion
by
Whang, byung-woo
Aug 21, 2025 06:06am
The influence of Nubeqa (darolutamide) is rising in the market with the company expanding its indication as a treatment for metastatic hormone-sensitive prostate cancer (mHSPC). Experts believe that the drug may settle as a flexible treatment option in Korea¡¯s market as it has broadened its path as a personalized treatment. With the approval
Company
Reimb of polycythemia vera drug 'BESREMi' likely in Sept
by
Eo, Yun-Ho
Aug 21, 2025 06:06am
The polycythemia vera treatment 'BESREMi' is expected to be listed on the national health insurance list. The National Health Insurance Service (NHIS) and PharmaEssentia Korea have recently reached a final agreement on the drug price negotiation for BESREMi (ropeginterferon alfa-2b). As a result, if it passes the Health Insurance Policy Re
Company
Viatris signs exclusive sales and distribution deal for Brid
by
Whang, byung-woo
Aug 21, 2025 06:05am
Viatris Korea announced on the 20th that it has signed an exclusive domestic promotion and distribution agreement for the general anesthesia reversal agent Bridion (Sugammadex) through a strategic partnership with MSD Korea. Under the agreement, Viatris Korea officially took over the domestic promotion and distribution of Bridion as of th
Company
Generics challenge the patent of mkt leading 'Rinvoq'
by
Kim, Jin-Gu
Aug 21, 2025 06:05am
The patent challenges by generics targeting AbbVie's Janus kinase (JAK) inhibitor' Rinvoq (upadacitinib)' have begun. The pharmaceutical industry anticipates that patent challenges will further expand as Rinvoq strengthens its monopolistic position in the JAK inhibitor market, which is valued at approximately KRW 62 billion annually.
Company
Expanded patent dispute over cancer drug 'Xtandi'
by
Kim, Jin-Gu
Aug 20, 2025 06:22am
The number of companies challenging the patent for Astellas' prostate cancer treatment, 'Xtandi (enzalutamide)', has expanded to six. Attention has been drawn to the fact that major pharmaceutical companies, such as Chong Kun Dang, Hanmi Pharmaceutical, and JW Pharmaceutical, have joined this latest patent challenge. According to the phar
1
2
3
4
5
6
7
8
9
10
>